Free Practice Questions for Romania Residency Admission — Pharmacy

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card

93+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More Romania National Medical Residency Admission (Concurs Național de Rezidențiat)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Romania Concurs Național de Rezidențiat — Medicină

Practice Questions100 questions

Romania Concurs Național de Rezidențiat — Medicină Dentară

Practice Questions100 questions

Sample Romania Residency Admission — Pharmacy Practice Questions

Try these sample questions to review concepts for the Romania Residency Admission — Pharmacy exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 93+ question experience with AI tutoring.

1An intravenous bolus dose of 500 mg of an antibacterial agent is administered to an adult patient. By extrapolating the initial monoexponential plasma concentration-time curve back to time zero, the initial plasma concentration (C0) is determined to be 25 mg/L. What is the apparent volume of distribution (Vd) of this drug?

A.12.5 L

B.20 L

C.25 L

D.50 L

Explanation: The apparent volume of distribution for an intravenous bolus obeying one-compartment kinetics is calculated using Vd = Dose / C0. Substituting the values: Vd = 500 mg / (25 mg/L) = 20 L. This parameter reflects the theoretical volume required to contain the total drug amount at the concentration observed in plasma.

2A novel cardiovascular agent follows first-order elimination kinetics with an elimination rate constant (ke) of 0.05 h⁻¹. What is the elimination half-life (t1/2) of this drug?

A.6.93 hours

B.10.0 hours

C.13.86 hours

D.20.0 hours

Explanation: For first-order elimination kinetics, the relationship between elimination rate constant and half-life is defined by t1/2 = ln(2) / ke ≈ 0.693 / ke. With ke = 0.05 h⁻¹, t1/2 = 0.693 / 0.05 h⁻¹ = 13.86 hours.

3A drug has an apparent volume of distribution of 40 L and an elimination rate constant of 0.07 h⁻¹. What is the total systemic clearance (Cl) of the drug?

A.0.57 L/h

B.1.75 L/h

C.2.8 L/h

D.5.7 L/h

Explanation: Systemic clearance is mathematically related to the apparent volume of distribution and the elimination rate constant by Cl = ke * Vd. Calculating: Cl = 0.07 h⁻¹ * 40 L = 2.8 L/h.

4In a hypothetical linear one-compartment calculation, an oral drug has Vd 50 L and bioavailability 0.75. What calculated loading dose corresponds to a target concentration of 15 mg/L? This is a calculation exercise, not a prescribing recommendation.

A.562.5 mg

B.750 mg

C.1000 mg

D.1250 mg

Explanation: The oral loading dose accounts for bioavailability: Loading Dose = (Ctarget * Vd) / F. First, calculate the systemic amount required: 15 mg/L * 50 L = 750 mg. Next, adjust for 75% bioavailability: 750 mg / 0.75 = 1000 mg.

5An intensive care patient requires a continuous intravenous infusion of theophylline to maintain a steady-state plasma concentration (Css) of 10 mg/L. The patient's total clearance is determined to be 3.0 L/h. What infusion rate (R0) is required?

A.3.3 mg/h

B.15.0 mg/h

C.30.0 mg/h

D.300.0 mg/h

Explanation: At steady state during continuous intravenous infusion, the rate of drug administration equals the rate of drug elimination: Infusion Rate (R0) = Css * Cl. Substituting: R0 = 10 mg/L * 3.0 L/h = 30.0 mg/h.

6A constant-rate IV infusion starts from zero drug concentration, without a loading dose. Assume a linear one-compartment model and an elimination half-life of 8 hours. How long is needed to reach 90% of steady state?

A.8 hours

B.16 hours

C.26.6 hours

D.40 hours

Explanation: The fraction of steady-state achieved during constant infusion is 1 - (0.5)^n, where n is the number of half-lives. For 90% Css: 1 - 0.5^n = 0.90, so 0.5^n = 0.10, giving n = -ln(0.10)/ln(2) ≈ 3.32 half-lives. Multiplying 3.32 * 8 hours = 26.56 ≈ 26.6 hours. As a rule of thumb, reaching 90% steady state requires approximately 3.3 half-lives.

7In a specified receptor-response system, which description best characterizes an agonist with lower efficacy than the reference full agonist?

A.An agent that reduces constitutive receptor activity below baseline

B.A partial agonist that can produce a lower maximum response in this system and reduce the effect of a competing full agonist

C.An agent that binds to an allosteric site and irreversibly prevents agonist dissociation

D.An agent that produces a maximal response identical to the endogenous ligand but with lower potency

Explanation: Partial agonism is defined relative to a reference agonist and response system. A lower-efficacy agonist can compete with a full agonist and reduce its response. Receptor reserve and coupling efficiency affect the observed maximum, so an agent need not show the same degree of partial agonism in every tissue.

8In receptor pharmacology, what shift occurs on a graded log concentration-response curve when a competitive reversible antagonist is added?

A.Parallel rightward shift with unchanged maximal response (Emax) and increased EC50

B.Downward shift with decreased Emax and unchanged EC50

C.Parallel leftward shift with increased potency and unchanged Emax

D.Non-parallel rightward shift with decreased Emax and decreased EC50

Explanation: Competitive reversible antagonists compete with the agonist for the same orthosteric binding site. Higher concentrations of the agonist can overcome the blockade, preserving the maximal attainable effect (Emax remains unchanged), while higher agonist concentrations are needed for any given submaximal response (EC50 increases, shifting the curve in parallel to the right).

9What is the primary cellular mechanism of action of angiotensin-converting enzyme (ACE) inhibitors such as enalaprilat and ramiprilat?

A.Direct antagonism of angiotensin II type 1 (AT1) G-protein coupled receptors

B.Inhibition of the zinc metallopeptidase that converts angiotensin I to angiotensin II and inactivates bradykinin

C.Blockade of renin release by juxtaglomerular granular cells via beta-1 adrenoreceptors

D.Direct opening of ATP-sensitive potassium channels in vascular smooth muscle

Explanation: ACE (peptidyl-dipeptidase A) is a zinc-containing metalloproteinase that catalyzes the cleavage of the C-terminal dipeptide His-Leu from decapeptide angiotensin I to form the potent octapeptide vasoconstrictor angiotensin II. It also degrades vasodilator peptide bradykinin. ACE inhibitors competitively bind the active zinc site, suppressing angiotensin II generation and stabilizing bradykinin.

10Which of the following beta-adrenergic antagonists possesses both beta-1 selectivity and endothelium-dependent nitric oxide (NO)-mediated vasodilating activity?

A.Propranolol

B.Atenolol

C.Nebivolol

D.Carvedilol

Explanation: Nebivolol combines preferential beta-1 blockade with nitric-oxide-mediated vasodilating activity. Carvedilol instead combines nonselective beta blockade with alpha-1 antagonism. Receptor selectivity is dose dependent and does not eliminate all beta-2 effects.

About the Romania Residency Admission — Pharmacy Exam

Independent practice for Concursul Național de Rezidențiat — Farmacie and selected pharmaceutical subjects. The official Romanian-language admission contest is scheduled for 15 November 2026. This English-language MCQ study adaptation uses four options and one correct answer. It is not an official translation, a full format simulation, or a substitute for the official bibliography, Romanian examination reading, or laboratory and practical training.

Exam sponsor: Ministerul Sănătății (Ministry of Health), with six university centers. The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Questions

200 questions

Time Limit

240 minutes (4 hours)

Passing Score

60% of the highest national pharmacy score; ranking and available places/posts determine allocation

Exam / Certification Fees

500 lei (2026 session)

Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Official sources

2026 contest publication · Source checked 2026-10-10Ministry publication hosted by UMF Carol Davila: session, registration requirements, and 500 lei fee.
2026 contest methodology · Source checked 2026-10-10Official Gazette methodology: 200 questions, four hours, scoring, eligibility, and ranking.
2026 pharmacy topics and bibliography · Source checked 2026-10-1037 themes using the revised second edition of Manual pentru admiterea în rezidențiat, domeniul Farmacie, 2026, plus specified legal reading.
Pharmacist Deontological Code · Source checked 2026-10-10Decision 2/2009 includes the code; the specified ethics reading is distinct from the separate CFR Statute.

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

27 practice questions

Pharmacology and pharmacotherapy

Drug mechanisms, kinetics, interactions, and selected therapeutic agents.

28 practice questions

Pharmaceutical technology and biopharmacy

Formulations, manufacturing, dosage forms, and biopharmaceutics.

2 practice questions

Pharmaceutical analysis

Absorbance and chromatographic retention calculations.

12 practice questions

Pharmacognosy and phytotherapy

Selected phenolic constituents and anthraquinone derivatives.

17 practice questions

Clinical pharmacy and toxicology

Dosing, adverse reactions, pregnancy counseling, and poisoning mechanisms.

7 practice questions

Professional legislation and ethics

Professional practice, continuing education, delegation, publicity, and confidentiality. These are bank counts, not official weights. Coverage is selective, including limited analysis practice and no comprehensive substances-of-abuse section.

Preparing for the Romania Residency Admission — Pharmacy Exam

What You Need to Know

Passing score: 60% of the highest national pharmacy score; ranking and available places/posts determine allocation
Exam length: 200 questions
Time limit: 240 minutes (4 hours)
Exam / certification fees: 500 lei (2026 session) Official sources

Using Our Practice Resources

Work through all 93 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Romania Residency Admission — Pharmacy: Suggested Study Strategy

1Use the revised 2026 manual and exact legal provisions specified by the official reading list.

2Keep units explicit in calculations; loading dose = target concentration × volume of distribution / bioavailability under the stated model.

3Practice Romanian pharmaceutical terminology and the official multiple-answer selection rules separately.

4Supplement this bank with the remaining official themes, especially substances of abuse, analysis, and practical laboratory skills.

Frequently Asked Questions

What is the official assessment format?

A four-hour Romanian-language written contest with 200 five-option items: 50 with one correct answer and 150 with two to four correct answers. The ordinary admission assessment has no separately graded oral examination, practical test, assignment, or case-study submission.

Does reaching 60% guarantee a residency place?

No. The threshold is 60% of the highest achieved national pharmacy score. Eligible candidates choose within the available places/posts in ranking order.

Which reading list applies in 2026?

The 37-theme list specifies the revised second edition of the pharmacy residency admission manual, 2026, Law 95/2006 Title XIV with listed amendments, and the Deontological Code under Decision 2/2009. Study the whole official list; this bank covers selected subjects and is not a full examination simulation.